InsiderTrades.com logo
$2 Trillion Disappears Because of Fed's Secretive New Move
From Stansberry Research   |   Ad
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Click here to see his new research now.
Lucy Lu net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Lucy Lu Biography and Net Worth

Director of Veru
Lucy Lu, M.D. rejoins the Veru Board in May 2021 after previously serving as a Director of the Company from 2016 to 2019. Dr. Lu is the President and Chief Executive Officer of Avenue Therapeutics, Inc. From 2012 to 2017, Dr. Lu was the Chief Financial Officer of Fortress Biotech, Inc. Prior to working in the biotech industry, Dr. Lu had 10 years of experience in healthcare-related equity research and investment banking. From 2007 to 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee’s College of Arts and Science.

What is Lucy Lu's net worth?

The estimated net worth of Lucy Lu is at least $3,250.00 as of May 11th, 2017. Dr. Lu owns 5,000 shares of Veru stock worth more than $3,250 as of December 22nd. This net worth estimate does not reflect any other investments that Dr. Lu may own. Learn More about Lucy Lu's net worth.

How do I contact Lucy Lu?

The corporate mailing address for Dr. Lu and other Veru executives is 48 NW 25th Street Suite 102, Miami FL, 33127. Veru can also be reached via phone at (305) 509-6897 and via email at [email protected]. Learn More on Lucy Lu's contact information.

Has Lucy Lu been buying or selling shares of Veru?

Lucy Lu has not been actively trading shares of Veru over the course of the past ninety days. Most recently, on Tuesday, August 17th, Lucy Lu bought 4,800 shares of Veru stock. The stock was acquired at an average cost of $6.78 per share, with a total value of $32,544.00. Learn More on Lucy Lu's trading history.

Who are Veru's active insiders?

Veru's insider roster includes Harry Fisch (Director), and Lucy Lu (Director). Learn More on Veru's active insiders.

Are insiders buying or selling shares of Veru?

During the last year, Veru insiders bought shares 2 times. They purchased a total of 11,711 shares worth more than $16,699.39. During the last year, insiders at the sold shares 4 times. They sold a total of 181,970 shares worth more than $250,075.35. The most recent insider tranaction occured on May, 24th when insider K Gary Barnette bought 5,000 shares worth more than $6,700.00. Insiders at Veru own 14.2% of the company. Learn More about insider trades at Veru.

Information on this page was last updated on 5/24/2024.

Lucy Lu Insider Trading History at Veru

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/17/2021Buy4,800$6.78$32,544.00View SEC Filing Icon  
5/11/2017Buy5,000$1.00$5,000.005,000View SEC Filing Icon  
See Full Table

Lucy Lu Buying and Selling Activity at Veru

This chart shows Lucy Lu's buying and selling at Veru by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Veru Company Overview

Veru logo
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $0.65
Low: $0.63
High: $0.68

50 Day Range

MA: $0.74
Low: $0.58
High: $0.93

2 Week Range

Now: $0.65
Low: $0.36
High: $1.92

Volume

1,501,317 shs

Average Volume

1,599,478 shs

Market Capitalization

$95.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
$2 Trillion Disappears Because of Fed's Secretive New Move
From Stansberry Research   |   Ad
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Click here to see his new research now.